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Background/aim: We aimed to report outcomes of pregnant patients with asthma under omalizumab treatment and their infants in
our country.
Materials and methods: Patients with asthma who received omalizumab for at least 6 months and at least one dose during their
pregnancy were retrospectively evaluated using a questionnaire regarding their disease and therapy and the health of their infants.
Results: Twenty pregnant patients and their 23 infant’s data were analyzed. The mean delivery age was 31.8 ± 7.4 years. They received
omalizumab for 28.9 ± 21.8 months. Eight (36.4%) patients showed exacerbation of the disease during pregnancy. Forced expiratory
volume in 1 s (FEV1) and asthma control test (ACT) scores at the starting time of omalizumab administration, first month of the
pregnancy, and after delivery were 71 ± 18%, 83.4 ± 10.5%, and 80.5 ± 13% (FEV1), and 11.9 ± 4.9, 20.2 ± 2.6, and 20.4 ± 2.2 (ACT),
respectively. One patient gave birth to twin infants, two patients to two infants each in different years, and 17 to one infant each. Three
(13%) infants had low birth weight and five (21.7%) were born prematurely. No congenital anomalies were detected. Seven (30.4%)
infants presented atopic diseases during their life.
Conclusion: Omalizumab treatment during pregnancy seems to be safe for both patients and their infants.
Key words: Exacerbation, gestation, infant, omalizumab, pregnancy, prematurity

1. Introduction
Asthma affects 330 million individuals worldwide and
around 4 million in Turkey [1,2]. This disease has been
reported in 8% of pregnant individuals [3,4]. The health
condition of one-third of pregnant patients with asthma is
not affected by the physiological, hormonal, and immune
changes that occur during the gestation period, one-third
shows improvement, and one-third shows progression and
ingravescence [3,4].

There are sufficient data concerning the continuation
of satisfactory asthma control during pregnancy and
therefore appropriate asthma treatment for pregnant
women with asthma to deliver a healthy infant [5]. In this
context, many reports on omalizumab, which is used by
severe allergic asthma patients during pregnancy, have
been published [6,7]. The Observational Study of the Use
and Safety of Xolair® (omalizumab) during pregnancy
(EXPECT), the largest prospective study on this subject,
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which has examined 228 pregnant women and 233
infants, identified a birth anomaly rate of 8.1% and
preterm delivery rate of 15%. These rates are not different
from the outcomes of the Quebec External Comparator
Cohort (QECC) study, which involves the most extensive
overall cohort of pregnant women with asthma [6]. In
addition, in EXPECT vs. QECC, there was a lower rate
of small for gestational age (SGA) infants of mothers
receiving omalizumab (9.7% vs. 15.8%) [6]. In contrast, in
the position paper of the European Academy of Allergy
and Clinical Immunology (EAACI) Society regarding
the administration of biological drugs for allergy during
gestation, the rates of congenital anomalies and low birth
weight have been reported as 4% each and that of preterm
birth in singletons as 14% for omalizumab, based on the
outcomes of 11 different publications [7].
Real-life data on the efficacy of omalizumab in patients
with asthma have been collected and released in Turkey;
however, no data related to gestation have been reported
[8]. Although the case notices of all studies conducted
previously across the world reported that the administration
of omalizumab is safe in gestation, the number of pregnant
patients in these case series was between one and four, and
there was only one observational study from the United
States [6,7]. In our study, we worked with the real-life
data sample reported from one country: 22 pregnancies
and 23 infants. Therefore, we aim to share our experience
regarding the safety of omalizumab in both mothers and
infants by a retrospective review of the relevant data from
Turkey.
2. Materials and methods
This retrospective real-life case study was approved by the
Institutional Ethic Committee (06.08.2019 date 83045809604.01.02-123451 number); Helsinki Declaration was
signed by all coauthors. Informed consent was obtained
from each patient.
The centers participating in the Turkish omalizumab
data survey were called for participation in this study [8].
Nine centers participated in the study as they had pregnant
patients under omalizumab therapy with born infants.
This study was conducted in Turkey from August 15,
2019 to October 31, 2019. A structured questionnaire was
prepared by the authors to collect information regarding
demographic and clinical parameters of the mothers as
follows; age, living area, smoking status, body mass index,
occupation, education level, prick test results and total
IgE levels at the beginning of omalizumab administration;
spirometry, asthma control test (ACT), and whole
blood count results at the beginning of omalizumab
administration, beginning of the pregnancy, and after the
delivery of the infant; exacerbation rate and exacerbation
trimester time during pregnancy and last year before
pregnancy; treatment-related parameters (adherence);

infant demographic parameters and health during the
whole breastfeeding period, until the end of the study.
Patients with asthma who received omalizumab for at
least 6 months and at least one dose during pregnancy
and had a live birth were retrospectively evaluated using a
questionnaire. The data not present in the file of the patient
were collected via the questionnaire prepared by the
authors when the patients came to the relevant clinics for
their omalizumab injections after having their informed
consent. The outcome or the safety of omalizumab was
attributed as the control status and the exacerbation rate of
the pregnant patient, the APGAR score, the prematurity,
the birth weight, the rate of malformation, and the allergic
diseases of the infants.
The data of the patients are presented as exact numbers
and percentages. If numerical variables are normally
distributed, they are presented as mean ± standard
deviation. Nonnormally distributed data are presented as
median (min-max). The evaluation of spirometry data,
ACT scores, and whole blood count data at different time
points were compared using the Friedman variance analysis
and the Wilcoxon signed rank test. Pearson’s correlation
test was used when two variables were continuous. All
data were evaluated within a 95% confidence interval with
a significance level of p < 0.05. All statistical analyses were
performed using SPSS Version 20.0 (IBM Corp. 2012).
3. Results
The data correspond to 20 pregnant patients with asthma
(22 singleton pregnancies, 1 twin pregnancy) and their 23
infants. One patient gave birth to twin infants, two patients
to two infants each in different years, and 17 to one infant
each when they were on omalizumab.
3.1. Maternal demographics and clinical characteristics
Four patients (18%) were over 34 years old. The majority
of the patients lived in urban areas (95.5%), and 59%
were housewives. The mean asthma duration before
treatment with omalizumab was 12.2 ± 8.1 years (range,
2–40 years). All patients were allergic to house dust mite
(Dermatofagoides pteronissymus). Five of them had also
mold allergy (alternaria) and 2 of them also had cockroach
positive skin prick test. Their total serum IgE level was 242.1
± 198.8 IU in the beginning of omalizumab treatment.
Exacerbation rate (requiring oral corticosteroid treatment
for 3 or more days) last year before pregnancy was 40%.
Only eight (36.4%) of the patients showed exacerbation
(requiring oral corticosteroid treatment for 3 or more days)
during pregnancy and half of the exacerbation were in the
third trimester. All of them used inhaled corticosteroids
(ICS) and long-acting beta-agonists (LABA) with high
adherence level in 86.4% of the pregnancies. Demographic
and clinical data of the patients are presented in Table 1.
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Table 1. Maternal demographics and clinical and therapeutic characteristics of 22 pregnancies.
Age (years)
Mean ± standard deviation (SD)
N, % <34 y
Living area (N and %)
Urban
Rural
Education (N and %)
Illiterate
Primary school
High school
University
Occupation (N and %)
Housewife
Officer
Self-employed
Asthma history before omalizumab (years)
Median (range: min–max)
Smoking history (N and %)
Body mass index (BMI) (kg/m2
Median (range: min–max)
BMI > 30 (obesity) ( N, %)
Comorbidities (N and %)
Allergic rhinitis
Exacerbation rate before pregnancy (last year, with oral corticosteroids) (N and %)
Exacerbation rate during pregnancy (with oral corticosteroids) (N and %)
1 exacerbation case (N and %)
2 exacerbation cases (N and %)
Exacerbation time during pregnancy
First trimester (N and %)
Second trimester (N and %)
Third trimester (N and %)
Medications other than omalizumab (N and %)
Inhaled corticosteroid (ICS)
ICS + long acting beta agonist (LABA)
Leukotrien receptor antagonists (LTRA)
Tiotropium
Histamine1 receptor antagonists*
Nasal corticosteroids
Adherence to medications other than omalizumab (N and %)
High adherence**
Medium adherence**
Low adherence**
Nonadherence**

31.8 ± 7.4
4 (18%)
21 (95.5%)
1 (4.5%)
2 (9%)
6 (27.3%)
7 (31.8%)
7 (31.8%)
13 (59%)
7 (31.8%)
2 (9.1%)
10 (2–40)
1 patient ex-smoker (5 packs-year), 4.3%
24 (20–37)
5 (22.7%)
16 (72%)
9 (40%)
8 (36.4%)
3 (13.6%)
5 (22.7%)
3 (37.5%) of 8
1 (12.5%) of 8
4 (50%) of 8
2 (9.1%)
22 (100%)
15 (68.2%)
2 (9.1%)
6 (27.3%)
9 (40.9%)
19 (86.4%)
2 (9.1%)
1 (4.5%)
0

*Ketotifen or loratadine.
**High adherence defines the patients who use medications regularly, medium adherence defines the patients who use medications 1–3
days a week, low adherence defines those who use medications with severe interruptions more than 3 days a week, nonadherence defines
the patients who do not use medication.
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2.2. Maternal spirometry, ACT, and whole blood count
results
Spirometry parameters, ACT, and whole blood count
results at the starting time of omalizumab administration,
during pregnancy, and after delivery are presented in
Table 2. ACT score at the starting time of omalizumab
administration was statistically lower than the beginning of
pregnancy and after delivery. There were no considerable
differences between other results at the beginning of
pregnancy and after delivery. No correlation was found
between forced expiratory volume in 1 s (FEV1) and the
gestational week at the birth of the infant (p > 0.05).
2.3. Omalizumab exposure results
Omalizumab exposure level, interval, and duration are
presented in Table 3. The patients had asthma for 12.2 ±
8.1 years and they received omalizumab for 28.9 ± 22.3
months. The twins received only one dose of omalizumab,
one infant received the drug in the first trimester, four
infants in the second and third trimesters, and 16 infants
throughout the pregnancy and breastfeeding periods
(minimum 3 months, maximum 28 months with a median
13 months).
2.4. Pregnancy and infant outcomes
Ten patients were delivering their first infant. Seventeen
(73.9%) patients underwent a cesarean section. No labor
complications were noted. Pregnancy and infant outcomes
are given in Table 3. The mean maternal age at delivery
was 31.8 ± 7.2 years. No congenital anomalies were
detected. Seven infants had allergic diseases during their
lives. The median APGAR score for newborn infants was

9 (maximum 10, minimum 5). Only one newborn infant
had an APGAR score below 8 (5). The mean birth weight
was 3055.8 ± 563.3 g. Premature births were seen in five
patients (21.7%).
3. Discussion
In our study of 22 pregnancies and 23 infants, asthma
exacerbation was seen only in 36.4% of the pregnancies.
FEV1 levels, ACT scores, and eosinophilia at the start of
pregnancy were not statistically significantly different than
those after pregnancy (p > 0.05). The patients received
omalizumab for 28.9 ± 22.3 months before pregnancy.
The twins received only one dose of omalizumab, one
infant received it in the first trimester (two doses), four
infants in the second and third trimesters, and 16 infants
throughout the pregnancy and breastfeeding periods. No
malformations were detected in the newborns and only
one newborn had an APGAR index below 8. Nevertheless,
premature birth was seen in five infants (21.7%) and seven
infants had allergic diseases during their life.
Maternal age is an important risk factor for congenital
anomalies. The median age of our patients was 31 years
(range, 25–47 years). It was equal to that in the EXPECT
cohort and higher than that in the QECC cohort (31 and
27.7, respectively) [6]. Furthermore, the percentage of
subjects younger than 35 years was 82% in our study but
74.8% in the EXPECT cohort and 85.7% in the QECC
cohort [6]. However, the infants in our study did not
present any anomalies.
The majority of our patients were from urban areas
(95%), 59% were housewives, and 63.6% were high school

Table 2. Spirometry parameters, asthma control test (ACT) scores, and whole blood count results (mean ±
standard deviation (SD)).

Spirometry
FVC (L)
FVC (%)
FEV1 (L)
FEV1 (%)
FEV1/FVC
ACT (N: 22, 100%)
Whole blood count
Hemoglobin(g/dL)
Hematocrite (%)
MPV
Trombocytes/mm3
Eosinophils/mm3
Eosinophils (%)

Starting time of
omalizumab

Beginning of
pregnancy

After pregnancy
(1–3 months)

N: 22 (100%)
3.05 ± 0.55
83.6 ± 18.8
2.39 ± 0.80
71.0 ± 18.2
76.8 ± 20.4
11.95 ± 4.95
N: 22 (100%)
12.9 ± 1.0
37.6 ± 3.7
9.5 ± 1.8
271 545 ± 63 120
447.8 ± 297.1
4.58 ± 2.74

N: 19 (86.4%)
3.61 ± 0.55
92.3 ± 12.2
3.00 ± 0.95
83.4 ± 10.5
87.2 ± 21.5
20.16 ± 2.64
N: 19 (86.4%)
12.3 ± 1.2
35.9 ± 3.9
9.4 ± 1.8
273 263 ± 63 625
356.1 ± 246.9
2.92 ± 1.98

N: 21 (95.5%)
3.21 ± 0.49
89.9 ± 10.0
2.62 ± 0.78
80.5 ± 13.0
89.9 ± 10.0
20.40 ± 2.18
N: 21 (95.5%)
12.1 ± 1.5
34.4 ± 3.9
9.6 ± 1.7
262 571 ± 59 815
226.7 ± 198.7
1.81 ± 1.79

p
>0.05
>0.05
>0.05
>0.05
>0.05
<0.05
>0.05
>0.05
>0.05
>0.05
>0.05
>0.05
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Table 3. Omalizumab exposure, pregnancy, and infants outcomes.
Omalizumab exposure
Time before pregnancy (months) (mean ± SD)
Dose (mg)
150 (N and %)
225 (N and %)
300 (N and %)
375 (N and %)
Other (N and %)
Dose interval
Every 2 weeks (N and %)
Every 4 weeks (N and %)
Exposure time
1st trimester (N and %)
2nd trimester + 3rd trimester (N and %)
All trimesters and breastfeeding period (N and %)
Pregnancy and infant outcomes
Birth weight (mg) (mean ± SD)
All infants
Singletons
Twins
Low birth weight* (N and %)
All infants
Singletons
Twins
Birth height (cm) (mean ± SD)
Gestational age (weeks) (mean ± SD)
Premature birth** (N and %)
Sex: male/female (N and %)
APGAR Score
Median (range: min–max)
Low APGAR score*** (N and %)
Infants with any allergic diseases (N and %)
Actual age of infants (weeks) (mean ± SD) (range)

28.9 ± 22.3
4 (18.2%)
2 (9.1%)
11 (50%)
2 (9.1%)
3 (13.6%)
5 (22.7%)
17 (77.3%)
3 (13.6%)
4 (18.2%)
16 (69.6%)

3055.8 ± 563.3
3109.1 ± 540.3
2062.5 ± 12.5
3 (13.04%)
1 (4.76%)
2 (100%)
48.2 ± 3.7
37.3 ± 2.2
5 (21.7%)
9/14 (39.1/60.9%)
9 (5–10)
1 (4.76%)
6 (26.09%)
31.2 ± 28.9 (range: 7–120)

*Low birth weight was defined as <2.5 kg.
**Premature birth was defined as less than 37 weeks of gestation.
***Low APGAR score is defined as an APGAR score lower than 8

or university graduates. Compared with other pregnant
groups studied in our country, our pregnant patients with
asthma were more educated, had different occupations,
and were less commonly from rural areas [9]. Coming
from urban areas means more exposure to traffic pollution,
which may lead to preterm birth [10].
Only one patient was an ex-smoker. The major
comorbidity was allergic rhinitis (72%), and only
five patients (22.5%) were obese. In contrast, in the
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EXPECT study, the rate of obese patients was 46.7% [6].
Furthermore, our patients did not have comorbidities
such as diabetes, which might have increased the risk of
certain lung diseases in infants [11]. Maternal allergy was
not present in all infants. Only seven infants had allergic
diseases at time of the study.
Asthma duration before omalizumab administration
had a range of 2 to 40 years, and all the patients had been
using ICS and LABA combinations before and during their
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pregnancy. Other add-on drugs used during pregnancy
were also nonteratogenic; patients had used similar drugs
in EXPECT and QECC studies [6]. Moreover, whereas
Yilmaz et al. pointed out nonadherence to treatment in
pregnant asthma patients, we did not encounter it in our
patients [9]. High adherence to medications was found in
our study.
Exacerbation was observed in eight (36.4%) of our
patients. This rate is lower than that before pregnancy. In a
study conducted by Schatz et al., with 1739 pregnant patients
with asthma, 30% of the patients who had previously been
identified as having mild asthma had progressed towards
moderate to severe asthma, but in subjects with severe
asthma, only 23% had progressed towards moderate and
mild asthma [12]. Furthermore, Schatz et al. showed that
13% of mild, 16% of moderate, and 52% of severe asthma
cases presented at least one exacerbation case [12]. This
suggests that there is a correlation between asthma severity
and increased risk of exacerbation. The exacerbation was
reported to occur mostly between weeks 17 and 24; in
other words, mostly in the second trimester of gestation
[3]. In conclusion, even though pregnant women with
severe asthma are considered to be at higher risk of an
attack, the ones with mild asthma are also at risk.
Furthermore, it has been demonstrated that
inflammation is associated with a risk of lack of asthma
control, which is due to failure to administer ICS, decrease
in treatment adherence, or obesity [13]. Uncontrolled
maternal asthma results in poor outcomes in infants
[14]. Spirometry parameters, ACT scores, and whole
blood count results at the beginning of pregnancy and
after delivery showed nonconsiderable differences in our
patients. However, one-third of the exacerbation cases
resulted from oral steroid use. In contrast, an exacerbation
rate of up to 45% in pregnant patients with asthma has
been reported [4]. However, their exacerbation rate,
ACT score, and FEV1, as well as blood test results at the
beginning of pregnancy were not different from the ones
after pregnancy (p > 0.05); the decrease in eosinophil
count after pregnancy was also not significant (p > 0.05).
Similarly, Fazel et al. found nonconsiderable differences
in eosinophil levels between controlled and uncontrolled
pregnant patients with asthma and healthy pregnant
women [15]. Meanwhile, Palmsten et al. used a modified
ACT (p-ACT) [16]. They reported that lower p-ACT scores
were associated with previous exacerbation, and were not
associated with future exacerbation during pregnancy.
Furthermore, De Araujo et al. evaluated the importance
of ACT in pregnancy and pointed out that physicians did
not require spirometry to assess the level of asthma control
and that ACT can be used in the primary care of expectant
mothers with asthma [17].
The gestational median age was 37.3 years in our
patients, and there was a higher rate of cesarean section

(73.9%) in our study patients. Furthermore, five infants
(21.7%) had premature birth and three (13% of all infants)
had low birth weight. Compared to the EXPECT study, the
low birth weight rate was similar, but the premature birth
rate was higher in our study [6]. As mentioned in EXPECT
study among women who took any oral corticosteroid at
any time during pregnancy, the prevalence of premature
birth was 32.7% in their subcohort [6]. All of our five
patients with premature birth used oral steroids for their
exacerbation. Additionally, only one infant had a low
APGAR score, and we found that the seven infants with
allergic diseases demonstrated genetic predisposition,
and omalizumab did not have an effect in this situation.
Meanwhile, no considerable differences between mothers
with and without asthma regarding the duration of
gestation, birth weight, low APGAR scores, or neonatal
respiratory difficulties were found in the study by Fazel et
al. [15]. Furthermore, none of our patients had infants with
congenital anomalies; however, this may be due to our small
sample size. In fact, in 2008, Blais and Forget reported that
the malformation probability in 4300 pregnant women
with asthma was increased [18]. It has been reported that
this is particularly correlated with exacerbation in the first
trimester (odds ratio 1.48, 95% CI 1.04–2.09) [18]. The
most notable outcomes in this regard have been suggested
by a metaanalysis consisting of 40 studies and 1,637,180
individuals conducted by Murphy et al. in 2011 [19]. In
this study, it was observed that the risk of low birth weight
infants was increased in pregnant women with asthma
[relative risk (RR) 1.46, 95% confidence interval (CI) 1.22–
1.75], there was a slight decrease in intrauterine growth
(IUGR) (RR 1.22, 95% CI 1.14–1.31), preterm delivery was
increased (RR 1.41, 95% CI 1.22–1.61), and preeclampsia
risk was also slightly higher (RR 1.54, 95% CI 1.32–1.81)
[19]. It has been reported that IUGR and preterm delivery
are due to maternal hypoxemia and altered placental
function in asthma [20]. We did not find any correlation
between FEV1 and prematurity. In the study conducted by
Murphy et al., it was suggested that preterm delivery and
preeclampsia decreased upon ensuring control through
proper asthma treatment [19]. Thus, it can be concluded
that such complications occur due to the lack of proper
treatment.
There are some limitations to our study. As the study
was retrospective, we could not obtain all the data for
the whole duration of the pregnancies. Moreover, other
patients on omalizumab during pregnancy may exist in
our country; we presented only those cases for which the
physicians agreed to participate in the study.
In conclusion, about one-third of our patients with
severe asthma on omalizumab had exacerbation during
pregnancy. However, the spirometry, ACT scores, and
blood count results after the delivery of the infants were not
considerably different from those before pregnancy. Two-
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thirds of our patients received omalizumab throughout the
gestation and breastfeeding periods, and premature birth
was seen in one-fifth of the patients. Overall, omalizumab
treatment during pregnancy seems to be safe for both
patients and their infants.
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